{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:37:21Z","timestamp":1778711841744,"version":"3.51.4"},"reference-count":32,"publisher":"S. Karger AG","issue":"12","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Multiple myeloma is a so far incurable malignant plasma cell disorder. During the past 2 decades, treatment paradigms substantially changed when novel drugs were introduced initially in treatment of relapsed disease and subsequently also in first-line treatment. &lt;b&gt;&lt;i&gt;Summary:&lt;\/i&gt;&lt;\/b&gt; Up to now, first-line treatment differs between patients initially classified as transplant eligible and those who are considered as nontransplant eligible. Transplant-eligible patients receive a primary proteasome inhibitor (PI)-based induction which is being combined with an immunomodulating agent and a CD38-directed monoclonal antibody followed by high-dose melphalan therapy and autologous stem cell transplantation with subsequent maintenance treatment with lenalidomide. Patients who are considered as nontransplant eligible receive upfront treatment preferentially with a continuous combination treatment either with a CD38-directed monoclonal antibody in combination with the immunomodulating agent lenalidomide or a lenalidomide-PI combination followed by lenalidomide maintenance. &lt;b&gt;&lt;i&gt;Key Messages:&lt;\/i&gt;&lt;\/b&gt; Primary goal of the initiated treatment is to induce a rapid and deep remission which ideally leads to an eradication of the residual plasma cell clone in sense of a minimal residual disease negativity. Achievement of long-term remission with limited toxicity despite continuous treatment strategies and maintenance or improvement of life-quality is key. Despite successful treatment options, specific difficult-to-treat subgroups, especially patients with high-risk myeloma remain with inferior prognosis and a clear unmet need for novel therapeutic strategies. Future concepts will evaluate cellular treatments and other innovative immunotherapies in first-line treatment in curative intention. <\/jats:p>","DOI":"10.1159\/000520504","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T22:00:45Z","timestamp":1638568845000},"page":"690-699","source":"Crossref","is-referenced-by-count":17,"title":["Current Treatment Approaches to Newly Diagnosed Multiple Myeloma"],"prefix":"10.1159","volume":"44","author":[{"given":"Susanne","family":"Ghandili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja C.","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9248-588X","authenticated-orcid":false,"given":"Lisa Beatrice","family":"Leypoldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.380"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000365"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000528"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2019.37.15_suppl.8003"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000667"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007522"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0611"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003454"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30354-9"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30099-5"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00685"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30140-0"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0724-1"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33003-4"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32956-3"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0311-8"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30452-6"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008787"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/520504","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/520504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:30:02Z","timestamp":1745422202000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000520504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,3]]},"published-print":{"date-parts":[[2021,12,27]]}},"URL":"https:\/\/doi.org\/10.1159\/000520504","archive":["Portico"],"relation":{},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"value":"2296-5270","type":"print"},{"value":"2296-5262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}